Figure 5.

In vivo bioluminescence and PET/NIRF imaging of orthotopically-implanted HepG2 tumors. A) In vitro bioluminescence imaging demonstrated the successful, stable transfection of luc2 gene into HepG2. B) The growth of orthotopic HepG2 tumors was monitored by in vivo bioluminescence imaging. PET/NIRF imaging was performed in mice with confirmed tumors, approximately 3 weeks after implantation. C) Representative MIPs of coronal and sagittal PET images, 120 h post administration of ⁸⁹Zr-Df-YY146-ZW800. D) During necropsy, NIRF imaging also visualized tumor nodules with excellent spatial concordance with PET images. The red and yellow arrows point to multiple tumor nodules detected by PET and NIRF imaging.